National Bank of Canada
SLNO

National Bank of Canada’s Soleno Therapeutics SLNO Stock Holding History

National Bank of Canada’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1
Closed -$71 – 3202
2025
Q1 		$71 Buy
+1
New +$49 ﹤0.01% 2735
2024
Q4 		– Sell
-1
Closed -$50 – 3185
2024
Q3 		$50 Buy
+1
New +$48 ﹤0.01% 2590

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

National Bank of Canada's SLNO Position: Q2 2025 in Review

National Bank of Canada sold out of Soleno Therapeutics (SLNO) in Q2 2025, closing a stake of 1 share — an estimated $71 sold.

National Bank of Canada first reported a position in SLNO in Q3 2024 and held it in 2 quarters. The position peaked at $71 in Q1 2025. 233 funds tracked by Wall St. Rank hold SLNO as of Q2 2025.

  • National Bank of Canada reported no remaining Soleno Therapeutics position as of Q2 2025 after selling out during the quarter.
  • National Bank of Canada sold 1 Soleno Therapeutics share in Q2 2025, an estimated $71.
  • National Bank of Canada first reported a position in Soleno Therapeutics in Q3 2024 and held it in 2 quarters.
  • National Bank of Canada's Soleno Therapeutics position peaked at $71 in Q1 2025.
  • 233 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2025.

Based on National Bank of Canada's 13F filing for Q2 2025, filed 13 Aug 2025.